Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth

Yalda Zolghadri, Shreoshi Pal Choudhuri, Ozhan Ocal, Somayeh Layeghi-Ghalehsoukhteh, Feaven Berhe, Michael A. Hale, Thomas M. Wilkie

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that resists efforts to identify better chemotherapeutics. PDA is associated with chronic pancreatitis and acinar cell dedifferentiation. This reduces enzyme production by the exocrine pancreas, resulting in digestive insufficiencies. Malabsorption of partially digested food causes bloating, overfilled intestines, abdominal pain, excessive feces, steatorrhea, and malnutrition. These maladies affect quality of life and restrict treatment options for pancreatitis and PDA. Here, we characterize health benefits and risks of dietary pancreatic enzymes in three mouse models of PDA-KC, KCR8-16, and KIC. KC expresses oncogenic KrasG12D in pancreatic tissue whereas KCR8-16 also has deletions of the Rgs8 and Rgs16 genes. Rgs proteins inhibit the release of digestive enzymes evoked by G-protein–coupled–receptor agonists. KC and KCR8-16 mice developed dedifferentiated exocrine pancreata within 2 months of age and became malnourished, underweight, hypoglycemic, and hypothermic. KC mice adapted but KCR8-16 mice rapidly transitioned to starvation after mild metabolic challenges. Dietary pancreatic enzyme supplements reversed these symptoms in KC and KCR8-16 animals, and extended survival. Therefore, we tested the benefits of pancreatic enzymes in an aggressive mouse model of PDA (KIC). Median survival improved with dietary pancreatic enzyme supplements and was extended further when combined with warfarin and gemcitabine chemotherapy. However, dietary pancreatic enzymes stimulated tumor growth in the terminal stages of disease progression in KIC mice.

Original languageEnglish (US)
Pages (from-to)616-626
Number of pages11
JournalAmerican Journal of Pathology
Volume188
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Malnutrition
Adenocarcinoma
Health
Enzymes
Growth
Neoplasms
Exocrine Pancreas
gemcitabine
Cell Dedifferentiation
Steatorrhea
Thinness
Acinar Cells
Chronic Pancreatitis
Insurance Benefits
Warfarin
Starvation
Hypoglycemic Agents
Feces
Pancreatitis
Abdominal Pain

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA) : Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. / Zolghadri, Yalda; Pal Choudhuri, Shreoshi; Ocal, Ozhan; Layeghi-Ghalehsoukhteh, Somayeh; Berhe, Feaven; Hale, Michael A.; Wilkie, Thomas M.

In: American Journal of Pathology, Vol. 188, No. 3, 01.03.2018, p. 616-626.

Research output: Contribution to journalArticle

Zolghadri, Yalda ; Pal Choudhuri, Shreoshi ; Ocal, Ozhan ; Layeghi-Ghalehsoukhteh, Somayeh ; Berhe, Feaven ; Hale, Michael A. ; Wilkie, Thomas M. / Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA) : Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth. In: American Journal of Pathology. 2018 ; Vol. 188, No. 3. pp. 616-626.
@article{cb0b12cd694b40f6bffcc4afbfccb91a,
title = "Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth",
abstract = "Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that resists efforts to identify better chemotherapeutics. PDA is associated with chronic pancreatitis and acinar cell dedifferentiation. This reduces enzyme production by the exocrine pancreas, resulting in digestive insufficiencies. Malabsorption of partially digested food causes bloating, overfilled intestines, abdominal pain, excessive feces, steatorrhea, and malnutrition. These maladies affect quality of life and restrict treatment options for pancreatitis and PDA. Here, we characterize health benefits and risks of dietary pancreatic enzymes in three mouse models of PDA-KC, KCR8-16, and KIC. KC expresses oncogenic KrasG12D in pancreatic tissue whereas KCR8-16 also has deletions of the Rgs8 and Rgs16 genes. Rgs proteins inhibit the release of digestive enzymes evoked by G-protein–coupled–receptor agonists. KC and KCR8-16 mice developed dedifferentiated exocrine pancreata within 2 months of age and became malnourished, underweight, hypoglycemic, and hypothermic. KC mice adapted but KCR8-16 mice rapidly transitioned to starvation after mild metabolic challenges. Dietary pancreatic enzyme supplements reversed these symptoms in KC and KCR8-16 animals, and extended survival. Therefore, we tested the benefits of pancreatic enzymes in an aggressive mouse model of PDA (KIC). Median survival improved with dietary pancreatic enzyme supplements and was extended further when combined with warfarin and gemcitabine chemotherapy. However, dietary pancreatic enzymes stimulated tumor growth in the terminal stages of disease progression in KIC mice.",
author = "Yalda Zolghadri and {Pal Choudhuri}, Shreoshi and Ozhan Ocal and Somayeh Layeghi-Ghalehsoukhteh and Feaven Berhe and Hale, {Michael A.} and Wilkie, {Thomas M.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.ajpath.2017.11.014",
language = "English (US)",
volume = "188",
pages = "616--626",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA)

T2 - Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth

AU - Zolghadri, Yalda

AU - Pal Choudhuri, Shreoshi

AU - Ocal, Ozhan

AU - Layeghi-Ghalehsoukhteh, Somayeh

AU - Berhe, Feaven

AU - Hale, Michael A.

AU - Wilkie, Thomas M.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that resists efforts to identify better chemotherapeutics. PDA is associated with chronic pancreatitis and acinar cell dedifferentiation. This reduces enzyme production by the exocrine pancreas, resulting in digestive insufficiencies. Malabsorption of partially digested food causes bloating, overfilled intestines, abdominal pain, excessive feces, steatorrhea, and malnutrition. These maladies affect quality of life and restrict treatment options for pancreatitis and PDA. Here, we characterize health benefits and risks of dietary pancreatic enzymes in three mouse models of PDA-KC, KCR8-16, and KIC. KC expresses oncogenic KrasG12D in pancreatic tissue whereas KCR8-16 also has deletions of the Rgs8 and Rgs16 genes. Rgs proteins inhibit the release of digestive enzymes evoked by G-protein–coupled–receptor agonists. KC and KCR8-16 mice developed dedifferentiated exocrine pancreata within 2 months of age and became malnourished, underweight, hypoglycemic, and hypothermic. KC mice adapted but KCR8-16 mice rapidly transitioned to starvation after mild metabolic challenges. Dietary pancreatic enzyme supplements reversed these symptoms in KC and KCR8-16 animals, and extended survival. Therefore, we tested the benefits of pancreatic enzymes in an aggressive mouse model of PDA (KIC). Median survival improved with dietary pancreatic enzyme supplements and was extended further when combined with warfarin and gemcitabine chemotherapy. However, dietary pancreatic enzymes stimulated tumor growth in the terminal stages of disease progression in KIC mice.

AB - Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that resists efforts to identify better chemotherapeutics. PDA is associated with chronic pancreatitis and acinar cell dedifferentiation. This reduces enzyme production by the exocrine pancreas, resulting in digestive insufficiencies. Malabsorption of partially digested food causes bloating, overfilled intestines, abdominal pain, excessive feces, steatorrhea, and malnutrition. These maladies affect quality of life and restrict treatment options for pancreatitis and PDA. Here, we characterize health benefits and risks of dietary pancreatic enzymes in three mouse models of PDA-KC, KCR8-16, and KIC. KC expresses oncogenic KrasG12D in pancreatic tissue whereas KCR8-16 also has deletions of the Rgs8 and Rgs16 genes. Rgs proteins inhibit the release of digestive enzymes evoked by G-protein–coupled–receptor agonists. KC and KCR8-16 mice developed dedifferentiated exocrine pancreata within 2 months of age and became malnourished, underweight, hypoglycemic, and hypothermic. KC mice adapted but KCR8-16 mice rapidly transitioned to starvation after mild metabolic challenges. Dietary pancreatic enzyme supplements reversed these symptoms in KC and KCR8-16 animals, and extended survival. Therefore, we tested the benefits of pancreatic enzymes in an aggressive mouse model of PDA (KIC). Median survival improved with dietary pancreatic enzyme supplements and was extended further when combined with warfarin and gemcitabine chemotherapy. However, dietary pancreatic enzymes stimulated tumor growth in the terminal stages of disease progression in KIC mice.

UR - http://www.scopus.com/inward/record.url?scp=85042254219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042254219&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2017.11.014

DO - 10.1016/j.ajpath.2017.11.014

M3 - Article

C2 - 29248457

AN - SCOPUS:85042254219

VL - 188

SP - 616

EP - 626

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -